• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 cytokine storm: targeting the appropriate cytokine.

作者信息

Cron Randy Q

机构信息

Randy Cron, Children's of Alabama, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233-1711, USA.

出版信息

Lancet Rheumatol. 2021 Apr;3(4):e236-e237. doi: 10.1016/S2665-9913(21)00011-4. Epub 2021 Feb 3.

DOI:10.1016/S2665-9913(21)00011-4
PMID:33655221
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7906730/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da6a/7906730/cc939a21c39b/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da6a/7906730/cc939a21c39b/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da6a/7906730/cc939a21c39b/fx1.jpg

相似文献

1
COVID-19 cytokine storm: targeting the appropriate cytokine.新冠病毒细胞因子风暴：靶向合适的细胞因子。
Lancet Rheumatol. 2021 Apr;3(4):e236-e237. doi: 10.1016/S2665-9913(21)00011-4. Epub 2021 Feb 3.
2
Coagulopathy as a Prodrome of Cytokine Storm in COVID-19-Infected Patients.凝血功能障碍作为新冠病毒感染患者细胞因子风暴的前驱症状
Front Med (Lausanne). 2020 Oct 23;7:572989. doi: 10.3389/fmed.2020.572989. eCollection 2020.
3
Nutraceutical Targeting of Inflammation-Modulating microRNAs in Severe Forms of COVID-19: A Novel Approach to Prevent the Cytokine Storm.针对重症 COVID-19 中炎症调节微小 RNA 的营养保健品靶向治疗：预防细胞因子风暴的新方法
Front Pharmacol. 2020 Dec 11;11:602999. doi: 10.3389/fphar.2020.602999. eCollection 2020.
4
Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile.COVID-19中Th-17细胞免疫风暴综合征和神经症状的治疗前景：硫胺素的疗效与安全性、体外证据及药代动力学特征
medRxiv. 2020 Aug 25:2020.08.23.20177501. doi: 10.1101/2020.08.23.20177501.
5
Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?靶向淋巴细胞Kv1.3通道以抑制重症COVID-19中的细胞因子风暴：这能否成为一种新的治疗策略？
Drug Discov Ther. 2020 Jul 15;14(3):143-144. doi: 10.5582/ddt.2020.03046. Epub 2020 Jun 25.
6
The Management of Cytokine Storm in COVID-19.新型冠状病毒肺炎细胞因子风暴的管理
Acta Med Indones. 2020 Jul;52(3):306-313.
7
Cytokine Storm in Coronavirus Disease 2019 and Adult-Onset Still's Disease: Similarities and Differences.新型冠状病毒病 2019 中的细胞因子风暴与成人Still 病：相似与不同。
Front Immunol. 2021 Jan 19;11:603389. doi: 10.3389/fimmu.2020.603389. eCollection 2020.
8
When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.新冠病毒感染患者的细胞因子风暴何时开始？一种用于识别它的快速评分方法。
J Clin Med. 2021 Jan 15;10(2):297. doi: 10.3390/jcm10020297.
9
Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.水飞蓟宾与严重急性呼吸综合征冠状病毒2：双重靶向宿主细胞因子风暴和病毒复制机制用于COVID-19患者的临床管理
J Clin Med. 2020 Jun 7;9(6):1770. doi: 10.3390/jcm9061770.
10
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.噬血细胞性淋巴组织细胞增生症：COVID-19 大流行引发的综述。
Rheumatol Int. 2021 Jan;41(1):7-18. doi: 10.1007/s00296-020-04636-y. Epub 2020 Jun 25.

引用本文的文献

1
Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome.重症 COVID-19 细胞因子风暴综合征中的噬血细胞性淋巴组织细胞增生症基因变异
Viruses. 2025 Aug 8;17(8):1093. doi: 10.3390/v17081093.
2
Critical risks of haemoadsorption for COVID-19 patients and directions for future evaluations: a nationwide propensity score matched cohort study.COVID-19患者血液吸附的关键风险及未来评估方向：一项全国性倾向评分匹配队列研究
Sci Rep. 2025 Aug 9;15(1):29184. doi: 10.1038/s41598-025-13860-0.
3
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.

本文引用的文献

1
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.白细胞介素-1和白细胞介素-6抑制与COVID-19合并高炎症患者标准治疗的比较：一项队列研究
Lancet Rheumatol. 2021 Apr;3(4):e253-e261. doi: 10.1016/S2665-9913(21)00012-6. Epub 2021 Feb 3.
2
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
3
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.
一项关于IL-7用于新冠重症患者的随机、双盲、安慰剂对照试验。
JCI Insight. 2025 Feb 4;10(6):e189150. doi: 10.1172/jci.insight.189150.
4
IL-1 Family Blockade in Cytokine Storm Syndromes.白细胞介素-1 家族阻断在细胞因子风暴综合征中的应用。
Adv Exp Med Biol. 2024;1448:553-563. doi: 10.1007/978-3-031-59815-9_36.
5
COVID-19 Pneumonia and Cytokine Storm Syndrome.新型冠状病毒肺炎及细胞因子风暴综合征
Adv Exp Med Biol. 2024;1448:307-319. doi: 10.1007/978-3-031-59815-9_22.
6
A Comparative Analysis of MicroRNA Expression in Mild, Moderate, and Severe COVID-19: Insights from Urine, Serum, and Nasopharyngeal Samples.轻度、中度和重度 COVID-19 患者尿液、血清和鼻咽样本中 microRNA 表达的比较分析。
Biomolecules. 2023 Nov 21;13(12):1681. doi: 10.3390/biom13121681.
7
Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.COVID-19 细胞因子风暴中阿那白滞素随机安慰剂对照试验中 IL-6 对生存的预测。
Viruses. 2023 Sep 30;15(10):2036. doi: 10.3390/v15102036.
8
Cytokine-Induced iNOS in A549 Alveolar Epithelial Cells: A Potential Role in COVID-19 Lung Pathology.细胞因子诱导的A549肺泡上皮细胞中的诱导型一氧化氮合酶：在COVID-19肺部病理中的潜在作用
Biomedicines. 2023 Oct 3;11(10):2699. doi: 10.3390/biomedicines11102699.
9
Leukopenia and leukocytosis as strong predictors of COVID-19 severity: A cross-sectional study of the hematologic abnormalities and COVID-19 severity in hospitalized patients.白细胞减少和白细胞增多作为新冠病毒疾病严重程度的有力预测指标：一项关于住院患者血液学异常与新冠病毒疾病严重程度的横断面研究
Health Sci Rep. 2023 Sep 27;6(10):e1574. doi: 10.1002/hsr2.1574. eCollection 2023 Oct.
10
Role of Olive Bioactive Compounds in Respiratory Diseases.橄榄生物活性化合物在呼吸系统疾病中的作用。
Antioxidants (Basel). 2023 May 23;12(6):1140. doi: 10.3390/antiox12061140.
新型冠状病毒肺炎相关过度炎症综合征的临床标准：一项队列研究
Lancet Rheumatol. 2020 Dec;2(12):e754-e763. doi: 10.1016/S2665-9913(20)30343-X. Epub 2020 Sep 29.
4
Preliminary predictive criteria for COVID-19 cytokine storm.COVID-19 细胞因子风暴的初步预测标准。
Ann Rheum Dis. 2021 Jan;80(1):88-95. doi: 10.1136/annrheumdis-2020-218323. Epub 2020 Sep 25.
5
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
On the Alert for Cytokine Storm: Immunopathology in COVID-19.警惕细胞因子风暴：COVID-19 的免疫病理学。
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. doi: 10.1002/art.41285. Epub 2020 May 10.
8
Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.儿童炎症性疾病中的巨噬细胞活化综合征和继发性噬血细胞性淋巴组织细胞增生症：诊断与管理。
Paediatr Drugs. 2020 Feb;22(1):29-44. doi: 10.1007/s40272-019-00367-1.
9
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.阿那白滞素治疗儿童继发性噬血细胞性淋巴组织细胞增生症的获益。
Arthritis Rheumatol. 2020 Feb;72(2):326-334. doi: 10.1002/art.41103. Epub 2019 Dec 26.
10
The Immunology of Macrophage Activation Syndrome.巨噬细胞活化综合征的免疫学
Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119. eCollection 2019.